Research
Biotech company profiles
9 maintained profiles covering pipeline phase, disclosed cash runway, next expected data, and a plain-English read on what each company is actually betting on.
A company profile is maintained when we can say something specific and current about it: it has an upcoming tracked catalyst, or its cash runway is derivable from disclosed figures. Everything else is archived. A further 38 profiles are archived below: still readable, no longer reviewed. Looking for a name we do not cover? Run its trial through the Trial Translator.
Showing 9 of 9 published profiles
- CELCCelcuityApproved~41 mo runway
Oncology · 7 programs · Micro cap
Lead programs: REVTORPYK (gedatolisib) (HR+/HER2-, PIK3CA wild-type advanced breast cancer after endocrine therapy); Gedatolisib (HR+/HER2- advanced breast cancer (first-line)); G…
Next expected data
Gedatolisib — 2027
- CRSPCRISPR TherapeuticsApproved~75 mo runway
Cell & Gene Therapy · Hematology · Oncology · Rare Disease · 4 programs · Mid cap
CRISPR Therapeutics is, quite literally, the company that brought gene editing from science fiction to reality.
Next expected data
CTX110 — 2026
- EYPTEyePoint PharmaceuticalsPhase 3Runway under 12 mo
Ophthalmology · 10 programs · Micro cap
EyePoint Pharmaceuticals is a small biotech company that focuses on eye diseases.
Next expected data
EYP-1901 — Q4 2026
- NTLAIntellia TherapeuticsPhase 3~19 mo runway
Immunology & Inflammation · Oncology · Rare Disease · 2 programs · Mid cap
Intellia Therapeutics is trying to do something no company has ever done: prove that you can safely edit a person's genes while they're still inside their body.
Next expected data
NTLA-2002 — Phase 3 interim early 2026
- KROSKeros TherapeuticsPhase 2~65 mo runway
Hematology · 3 programs · Small cap
Keros Therapeutics is a biotech company that is trying to develop new medicines for rare diseases, which are conditions that affect a small number of people.
Next expected data
KER-065 — 2027
- KYTXKyverna TherapeuticsNDA/BLA filed~15 mo runway
Therapeutic focus not classified · 10 programs · Small cap
Kyverna Therapeutics is a biotech company that is trying to use a powerful cancer treatment to fight autoimmune diseases.
Next expected data
KYV-101 — Ongoing
- PRAXPraxis Precision MedicinesPhase 2~51 mo runway
Neuroscience · 3 programs · Small cap
Praxis Precision Medicines is a small biotech company that develops drugs for brain disorders like epilepsy and depression.
- VRTXVertex PharmaceuticalsApproved
Neuroscience · Rare Disease · 3 programs · Large cap
Lead programs: Trikafta (cystic fibrosis); Suzetrigine (acute and neuropathic pain); Casgevy (sickle cell disease and transfusion-dependent beta thalassemia).
- VKTXViking TherapeuticsPhase 3~13 mo runway
Cardiometabolic · 3 programs · Mid cap
Viking Therapeutics is one of the most talked-about small biotech companies in the market right now, and the reason is simple: they may have cracked the code on a weight-loss drug…
Next expected data
VK2735 (subcutaneous) — 2027 (Phase 3 VENTURE topline)
Archived profiles (38)
These pages are kept at their URLs and remain readable, but they are not reviewed or refreshed. Treat anything on them as a snapshot of when it was written.
- ABBVAbbVie
- ACADACADIA Pharmaceuticals
- ALNYAlnylam Pharmaceuticals
- AMGNAmgen
- FOLDAmicus Therapeutics
- ARGXargenx SE
- ARWRArrowhead Pharmaceuticals
- BEAMBeam Therapeutics
- BIIBBiogen
- BMRNBioMarin Pharmaceutical
- BNTXBioNTech
- BLUEbluebird bio
- SAVACassava Sciences
- DNLIDenali Therapeutics
- DYNDyne Therapeutics
- ERASErasca
- GILDGilead Sciences
- HALOHalozyme Therapeutics
- IMVTImmunovant
- INCYIncyte
- IONSIonis Pharmaceuticals
- KRTXKaruna Therapeutics
- LQDALiquidia Corporation
- MNMDMindMed
- MRTXMirati Therapeutics
- MRNAModerna
- MYGNMyriad Genetics
- NBIXNeurocrine Biosciences
- PVLAPalvella Therapeutics
- PRTAProthena
- RXRXRecursion Pharmaceuticals
- REGNRegeneron Pharmaceuticals
- RPRXRoyalty Pharma
- SRPTSarepta Therapeutics
- TNGXTango Therapeutics
- TERNTerns Pharmaceuticals
- RAREUltragenyx Pharmaceutical
- PCVXVaxcyte
Want the catalysts these companies are heading into?
The monthly catalyst calendar tracks the FDA decisions and data readouts across the sector, each with a plain-English read on what success and failure would look like.